Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
about
Drug delivery and nanoparticles:applications and hazardsSystemic delivery to central nervous system by engineered PLGA nanoparticlesDendrimer advances for the central nervous system delivery of therapeuticsNovel delivery strategies for glioblastomaSpinal cord injury: a review of current therapy, future treatments, and basic science frontiersNanoscale drug delivery systems and the blood-brain barrierUptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier modelStrategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties.Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cellsNanomedicine in the diagnosis and therapy of neurodegenerative disorders.Nanoparticulate transport of oximes over an in vitro blood-brain barrier model.Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies.Novel nanomaterials for clinical neuroscience.Agile delivery of protein therapeutics to CNSExploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiformeDevelopment of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.Nanoparticle-based targeted drug deliveryEffect of Nanosilver Particles on Procaspase-3 Expression in Newborn Rat Brain.Revolutionary impact of nanodrug delivery on neuroscience.Biomaterials for the central nervous systemBlood-brain barrier transport of therapeutics via receptor-mediationNanoparticles in modern medicine: state of the art and future challenges.Polymeric nanoparticles for the drug delivery to the central nervous system.Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy.A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles.Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier.Nano to micro delivery systems: targeting angiogenesis in brain tumors.The potential application of iron chelators for the treatment of neurodegenerative diseases.Drug delivery to the CNS and polymeric nanoparticulate carriers.Shuttle-mediated drug delivery to the brain.Nanowired drug delivery for neuroprotection in central nervous system injuries: modulation by environmental temperature, intoxication of nanoparticles, and comorbidity factors.Polymeric nanoparticles for drug delivery to the central nervous system.Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB.Which drug or drug delivery system can change clinical practice for brain tumor therapy?Peptide pills for brain diseases? Reality and future perspectives.Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.Nanocarrier-based therapies for CNS tumors.
P2860
Q24655744-DF5A928E-67EE-4DDE-ACA2-E5963520138AQ26751294-13BF4661-CC30-4E1C-A7B7-78C1ED1A2B11Q26828423-5DBA56BA-78AE-490E-B082-875F1680EA23Q27006099-9D14D123-B668-43C0-9879-3D67D0A71CB8Q27025166-13C6719B-2E3B-4D03-AB82-4927F9245ABFQ27026978-8A600848-886E-4C5C-997B-F8B6A47F4F9DQ28481345-8A8DEAA7-C2F5-44E5-84BA-C200F338538AQ30768284-9F7F8242-815D-4592-A2B1-552A2CD41D47Q33574182-DC0D3BF8-72A6-4C03-908A-74D402CBB0A9Q33726019-8782538D-96A7-474E-A1D8-1FB5E3380B45Q33769616-DDFBE338-4844-4AF2-83AF-65ECA67185B3Q33947926-C0E52580-A686-47DA-904A-6CE035A66C22Q33996836-71D70ED9-749B-4C00-A111-DEF30E0B054AQ34009532-C6D8460D-E7B2-49EB-9D10-0324A9947CA9Q34079647-58262E58-0E21-4A5C-AB4C-F03E6A6F3FC4Q34284213-3F0DE8EF-7F6E-44CC-8280-783936FBCFAAQ34791084-505272F1-FD5B-4A70-B9A4-29F68F64E22BQ35025058-42AFCD11-B066-4F0A-B1DE-32C172A80EE7Q35644991-4556D6F3-A9DC-4E3B-A554-898A5DF9FB6AQ36148782-A6C87F6A-D13D-4B08-A01F-A147C880FF46Q36460631-B182A1FE-7C0E-402F-9BA4-6E6A6C377690Q36777653-A20F56B6-16AF-4C16-9110-7FC7B8786087Q36874295-761EF9C8-CB7E-475F-BEC0-B39D7B2A6D34Q36920457-C671D5FB-E323-4C13-9A9C-98FC41526DB7Q37076360-10C81FF9-84AD-4679-8315-93FAFAF999E8Q37154213-59DEE53E-DFEE-477B-B27B-65EEEB501CC0Q37413195-1BAB2371-C767-4E41-BF2A-B786B2B6AC2FQ37668360-BE83B5F3-3596-45A1-A279-83BE205E7466Q37798870-8F89C8B1-BCD3-40B1-A081-62EC23C0D20CQ37846107-4251116E-7770-4C5E-AB7A-35D6005650C9Q37856301-7BB4FCD6-D2E4-425B-81BD-4F86167F45E2Q37896550-7CABEE4D-1D77-43A1-AA68-E78121F8C86CQ37967666-E3D1091E-A838-4E09-B89E-61D841E9EBAAQ37972516-850D9680-AAC0-4E5B-9905-CBF1F2693732Q37995554-5DA4468E-D24B-4324-9E9B-0791CBEA60B3Q38075010-9AD40966-3EF4-4320-ADE7-596203D49609Q38090394-59BBC9C6-6028-48DD-A8D2-814C30D03201Q38096036-EA768F2E-D7B3-46FE-9AB6-F391F6640217Q38133407-4AACF2FE-244E-4D6F-BD2A-16E861B01CCAQ38233169-E790AE43-06C6-4ECC-B1F5-368B3EA5EE78
P2860
Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Direct evidence that polysorbate-80-coated poly
@nl
Direct evidence that polysorba ...... of drug to the nanoparticles.
@en
type
label
Direct evidence that polysorbate-80-coated poly
@nl
Direct evidence that polysorba ...... of drug to the nanoparticles.
@en
prefLabel
Direct evidence that polysorbate-80-coated poly
@nl
Direct evidence that polysorba ...... of drug to the nanoparticles.
@en
P2093
P50
P356
P1476
Direct evidence that polysorba ...... of drug to the nanoparticles.
@en
P2093
David J Begley
Hagen von Briesen
Jörg Kreuter
Peter Ramge
Stefan Hamm
Valery Petrov
P304
P356
10.1023/A:1022604120952
P577
2003-03-01T00:00:00Z